PERSONALIZED PSYCHIATRY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The Personalized Psychiatry Market size is expected to reach US$ 7.16 billion by 2030, from US$ 3.54 billion in 2023, at a CAGR of 10.6% during the forecast period.

Personalized psychiatry involves using genetic, biological, and clinical data unique to each patient to develop targeted mental health treatments and therapies. It aims to move away from the one-size-fits-all approach to a more precise, individualized method. Some of the key technologies used include pharmacogenomic testing, quantitative EEG, computerized therapy programs, wearable biosensors, and molecular diagnostics. The main drivers of the market are growing awareness about mental health, advancements in genomic research and neurobiology, and the need for improved diagnosis and treatment outcomes in mental health.

The Personalized Psychiatry Market is segmented by product type, condition, end-user, and region. By product type, the software segment accounted for the largest share in 2022. The high share of this segment is attributed to the development of specialized algorithms and digital platforms that provide personalized mental health therapy based on patient data. Software allows for easy integration of various data sets and cost-effective delivery of tailored treatments.

Personalized Psychiatry Market Regional Insights:

• North America is expected to be the largest market for Personalized Psychiatry Market during the forecast period, accounting for over 40.5% of the market share in 2022. The growth of the market in North America is attributed to high adoption of advanced genomic testing, presence of leading providers, and increasing awareness about mental health.
• The Europe market is expected to be the second-largest market for Personalized Psychiatry Market, accounting for over 32.2% of the market share in 2022. The growth of the market in Europe is attributed to increasing R&D in neurobiology, favorable government initiatives, and launch of innovative digital therapeutics.
• The Asia Pacific market is expected to be the fastest-growing market for Personalized Psychiatry Market, with a CAGR of over 15.3% during the forecast period. The growth of the market in Asia Pacific is attributed to improving healthcare infrastructure, rising smartphone penetration, and growing target patient population.

Figure 1. Global Personalized Psychiatry Market Share (%), by Region, 2023

Personalized Psychiatry Market Drivers:

• Growing need for improved diagnosis and treatment outcomes in mental healthcare: The need for more accurate diagnosis and effective treatment of mental health disorders is a major driver boosting the personalized psychiatry market. The traditional trial-and-error approach to psychiatric care has limitations in terms of matching treatments to patients. Personalized testing and data-driven therapies can help overcome this by identifying biological factors influencing mental illness.For instance, pharmacogenomic testing determines how a person's genes affect their response to psychiatric medications. This allows doctors to make more informed prescribing decisions to avoid adverse events and improve outcomes. Using digital phenotyping through apps and wearables also facilitates continuous monitoring of symptoms to detect relapse early. Such technologies are enhancing the ability to diagnose and treat mental disorders in a targeted, patient-centric manner.
• Advancements in understanding of neurobiology and genetics of psychiatric illnesses: Rapid advances in research on the biological basis of mental disorders is further fueling the growth of personalized psychiatry. Technologies like neuroimaging and sequencing methods are unraveling the complex neurobiology underlying conditions like depression, schizophrenia, bipolar disorder etc.Identification of biomarkers related to neurotransmitters, neural circuits and genetic mutations is aiding development of more precise psychiatric treatments tailored to an individual. For example, presence of certain gene variants can predict which drug class will be most effective for a patient. Such discoveries regarding the molecular mechanisms of psychiatric diseases are propelling personalized medicine approaches.

• Growing adoption of precision medicine model in healthcare: The wider shift towards precision medicine across healthcare sectors is also driving adoption of personalized approaches in mental health. Precision techniques that provide custom-made therapies based on a patient's genes, biomarkers and lifestyle are gaining increasing acceptance. Mental health is at the forefront of this change due to its complexity. For instance, Stanford University launched a Center for Precision Mental Health & Wellness in 2018 dedicated to personalized psychiatry research. Such efforts to translate precision medicine into psychiatric care delivery are expected to transform the management of mental disorders.

• Increasing investments and partnerships focused on personalized mental healthcare: Rising investments and strategic partnerships between biopharma firms, health systems and tech startups to advance personalized psychiatry solutions is fueling market growth. Key players are collaborating to integrate biomarker testing, digital platforms, analytics and personalized medicine for better mental health outcomes. For example, in 2021 Pear Therapeutics partnered with Schwarz Group to launch digital therapeutics for multiple psychiatric conditions in Europe. Such initiatives focused on commercialization and real-world implementation of precision approaches continue to boost the market.

Personalized Psychiatry Market Opportunities:

• Scope for integration with telepsychiatry and remote patient monitoring: The COVID-19 pandemic heightened the scope for integrating personalized psychiatry with telemedicine to improve access and continuity of care. Remote delivery models like telepsychiatry and virtual therapy align well with personalized platforms involving genomic risk scores, digital therapeutics, mHealth apps and patient monitoring. Players like Teladoc Health, Amwell and MDLive can collaborate with personalized medicine startups working on precision mental health tools. Integrated telepsychiatry solutions combined with pharmacogenomic testing, digital phenotyping and analytics have huge potential to drive growth.

• Emergence of consumer-focused personalized psychiatry: Growing consumer interest in mental wellbeing has opened up opportunities for direct-to-consumer personalized psychiatry products. Startups like Genomind, BrightQuestMD and Real are offering psychiatric genetic testing and customized treatment plans directly to consumers. Demand for self-managed, genome-informed mental healthcare is rising. Players can tap this trend by providing consumers access to their genomic data, digital therapeutic apps, wearable mood trackers and personalized therapy. This can expand adoption beyond specialized clinics.

• Untapped potential in emerging economies: Emerging markets across Asia Pacific, Latin America and Middle East represent significant opportunities given the large underserved population and rising technology uptake. Digital health infrastructure is improving in these countries, creating avenues for personalized mobile psychiatry solutions. Companies can enter partnerships to develop customized tools that address challenges like lack of trained professionals, stigma and access barriers. Culturally tailored, evidence-based digital platforms combined with pharmacogenomics and biomarkers have huge scope in emerging economies.
• Development of ai-enabled personalized psychiatric care solutions: Advances in artificial intelligence and machine learning are opening up opportunities to automate and enhance various aspects of personalized psychiatry. AI can help derive insights from diverse patient datasets to enable adaptive and continuous care. For instance, AI can analyze facial expressions and speech patterns during virtual visits to detect early relapse signs. It can also predict optimal medications by discovering new genotype-phenotype associations from genetic data. AI-powered decision support tools can aid psychiatrists in treatment planning. Such AI applications can transform personalized psychiatry.

Personalized Psychiatry Market Trends:

• Focus on prevention and early intervention through personalized care: Shifting focus towards preventive psychiatry and early diagnosis is an emerging trend being facilitated by precision techniques. Companies are developing tools to assess individual risk profiles and enable timely interventions. For example, genetic testing firm Genomind offers a behavioral health genetic test to help identify risk for conditions like depression, anxiety, ADHD before onset of symptoms. Similarly, digital phenotyping through apps can track small changes in users' behaviors and moods predictive of mental illness. Preventive and preemptive psychiatry can help improve long-term prognosis.
• Growing research in biomarkers for mental health disorders: Considerable research is underway to identify and validate biomarkers that can accurately diagnose psychiatric conditions and predict treatment response. Biological markers like neuroimaging patterns, cognitive assessments, gene expression and blood-based protein biomarkers are being investigated. Companies like PsyberGuide are building platforms to deliver biomarker-based psychiatric treatment. Identifying and applying validated biomarkers in clinical practice will enable truly personalized therapies catered to the disease profile of each patient.
• Emergence of wearables and digital biomarkers for mental health monitoring: Advanced wearables such as smartwatches, patches and headbands that can continuously track physiological signals are gaining traction as digital biomarkers. They can capture heart rate variability, sleep patterns, skin temperature and other metrics indicative of mental health status. This approach of passively gathering real-world data is enabling personalized monitoring and diagnostics in psychiatry. Integration of such tools with EHRs and telemedicine provides physicians valuable insights into patients' mental state to guide care.
• Focus on evidence generation to demonstrate utility of personalized psychiatry: Generating robust evidence regarding clinical validity and utility of personalized medicine approaches is a key trend in the market. Companies are conducting more clinical studies and pilots to demonstrate meaningful improvements in real-world psychiatric treatment outcomes through precision techniques. Regulators are also increasingly demanding such evidence of benefit to patients. Development of best practices on scientifically sound applications of personalized care in mental health will support wider adoption.

Personalized Psychiatry Market Restraints:

• High costs and inadequate insurance coverage: The high costs of most personalized psychiatry interventions like pharmacogenomic testing, quantitative EEG, and prescribing genetic-guided medications are significant restraints limiting uptake. Many of these approaches are deemed experimental or investigational by payers and do not receive adequate insurance coverage. Lack of reimbursement mechanisms is a barrier for both providers and patients. Players need to take steps like generating strong efficacy data and collaborating with payers to establish coverage policies that make personalized psychiatry affordable.
• Addressing misconceptions regarding personalized medicine among clinicians: Some misconceptions exist among psychiatrists around the evidence base, utility and feasibility of applying personalized medicine in real-world practice. Many clinicians believe these approaches are still premature, expensive and disruptive to conventional workflows. Companies need to focus efforts on educating psychiatrists through medical bodies and conferences to increase mindshare. Establishing clinical utility through studies and pilots demonstrating meaningful improvements in patient outcomes can help overcome skepticism.
• Security and ethical concerns related to genetic testing: Concerns around privacy of sensitive genetic data, its potential for misuse in insurance and employment together with informed consent issues act as a drag on adoption of pharmacogenomic testing and other omics-based personalized care. Players in the market need to implement stringent data security safeguards and maintain highest ethical standards around transparent consent protocols and use restrictions to build patient and provider trust. Progress on the regulatory front in protecting genetic information and prohibiting its misuse can also help address these concerns.

Recent Developments:

New product launches:

• In January 2022, Akili Interactive launched EndeavorRx, the first FDA-cleared digital therapeutic for pediatric ADHD. EndeavorRx is delivered through a captivating video game experience designed to target and activate neural systems implicated in attentional function.
• In June 2021, Medopad partnered with eleven health to launch a digital biomarker platform for mental health. It captures active and passive data through apps and wearables to stratify patients and power personalized interventions.
• In May 2020, Mindstrong received FDA breakthrough designation for its digital biomarker tool to monitor cognitive health based on smartphone usage patterns. It aims to assist with diagnosis and treatment decisions for conditions like depression and anxiety.

Acquisition and partnerships:

• In January 2022, Happify partnered with Sanvello Health to merge digital mental health platforms. The partnership expands their ability to deliver clinically validated tools addressing stress, anxiety, and depression.
• In November 2021, Mindstrong collaborated with Behaivior to integrate passive mood monitoring capabilities into mental health virtual visits. This enhanced personalized care through continuous patient data collection.
• In October 2020, Medopad acquired Sherbit, an Israeli mental health startup, to enhance its digital biomarker portfolio with a focus on Alzheimer's disease and cognitive decline.

Figure 2. Global Personalized Psychiatry Market Share (%), by Product Type, 2023

Top companies in Personalized Psychiatry Market:

• myStrength
• Genomind
• WayForward
• BrightQuest
• Peak Mental Wellness
• Mindstrong
• Pear Therapeutics
• Akili Interactive
• Emotiv
• Neuronetrix
• Medopad
• Happify
• Taliaz
• Lucid Lane
• MindX Sciences
• Neurotrack
• 7 Cups
• Quartet
• NOCD
• Real

Definition: Personalized psychiatry is an emerging field in mental healthcare that involves using a patient’s unique genetic makeup, biology, and clinical presentation to provide tailored diagnosis, treatment, and management of psychiatric disorders. It combines various technologies like pharmacogenomics, quantitative EEG, digital phenotyping, and advanced analytics to move away from the one-size-fits-all approach and offer individualized care based on the patient’s specific parameters. Personalized psychiatry aims to improve clinical outcomes by identifying genetic biomarkers that can predict drug response, detect risk of side effects, and select optimal medications and doses for each patient. It also facilitates diagnosis of mental illness subtypes, early intervention, and tracking of treatment response through data derived from wearables, mobile apps, lab tests, and brain imaging. The global personalized psychiatry market is witnessing rapid growth driven by increasing research in neurobiology, advances in genomic testing, need for improved diagnosis and treatment, and emergence of technologies like AI, telehealth, and digital therapeutics. Personalized psychiatry has the potential to transform the future management of mental disorders through precision medicine.

Few Other Promising Reports in Pharmaceutical Industry:

Pharmacogenomics Market

Mental Health Software Market

Personalized Genomics Market

Genomic Cancer Testing Market